Trial Profile
Multicentre, Open-label, Randomised Study to Assess the Diagnostic Value of Amyloid PET Imaging in Patients with Subjective Cognitive Decline Plus, Mild Cognitive Impairment, or Dementia Where Alzheimer's Disease is in the Differential Diagnosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2018
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary) ; Flutemetamol-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Acronyms DPMS
- 26 Jun 2018 New trial record